NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01640405,Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells,https://clinicaltrials.gov/study/NCT01640405,VISNU-1,COMPLETED,The purpose of the study is to evaluate FOLFOX + bevacizumab versus FOLFOXIRI + bevacizumab as first line treatment of patients with metastatic colorectal cancer not previously treated and with three or more circulating tumoral cells.,NO,Metastatic Colorectal Cancer,DRUG: modified FOLFOX6 + bevacizumab|DRUG: FOLFOXIRI + Bevacizumab,"Progression free survival (PFS), 5 years","Overall survival (OS), 5 years|Response rate (RR), 5 years|Radical Resection (R0) surgery rate, 5 years|Circulating Tumour Cells (CTC) count basal and correlate to PFS, OS, RR, 5 years|Correlation of RAS, BRAF and PI3K mutations and clinical anti-tumour activity outcome ( PFS, OS, RR), 5 years|Adverse events, 5 years|Correlation of molecular status of bio markers related to the cellular and tumoral reproduction and/or mode of action and clinical anti-tumour activity outcome ( PFS, OS, RR), 5 years",,Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD),Roche Pharma AG,ALL,"ADULT, OLDER_ADULT",PHASE3,350,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,TTD-12-01|2012-000846-37,2012-07,2018-11,2018-11,2012-07-13,,2019-04-11,"Spanish Cooperative Group for Digestive Tumour Therapy, Madrid, 28046, Spain",
